Individual Stock News 1. Chow Tai Fook (01929.HK) issued a profit warning: It expects its annual net profit to increase by approximately 45-55% year-on-year. 2. GAC Group (02238.HK): April automobile sales reached 120,960 units, a year-on-year incr

2026-05-07

Individual Stock News 1. Chow Tai Fook (01929.HK) issued a profit warning: It expects its annual net profit to increase by approximately 45-55% year-on-year. 2. GAC Group (02238.HK): April automobile sales reached 120,960 units, a year-on-year increase of 3.88%. 3. Gemdale Properties & Investment (00535.HK): April contracted sales totaled approximately RMB 1.479 billion, a year-on-year increase of 73.39%. 4. Muyuan Foods (02714.HK): April sales revenue from commercial pigs was approximately RMB 8.503 billion, a year-on-year decrease of 32.49%. 5. Orient Securities (03958.HK): Plans to acquire 100% equity of Shanghai Securities through the issuance of A-shares and cash payment. 6. Minsheng International (00938.HK) issued a profit warning: It expects its annual pre-tax profit to be approximately HKD 399 million to HKD 442 million, turning a loss into a profit year-on-year. 7. BeiGene (06160.HK): First-quarter global revenue reached approximately US$1.513 billion, a year-on-year increase of 35%; adjusted operating profit was approximately US$414 million, a year-on-year increase of 197%; adjusted net profit was approximately US$375 million, a year-on-year increase of 175%. 8. LuKong (06623.HK): Received notification from the NYSE regarding compliance with the NYSE's continuing listing standards. 9. Midea Group: Plans to issue two batches of convertible bonds totaling HK$17.248 billion. 10. Shijiazhuang Pharmaceutical Group (02005.HK): Two medical device products have obtained medical device registration certificates issued by the Hebei Provincial Drug Administration of China. 11. CITIC Resources (01205.HK): Plans to sell a portion of its Alcoa shares, with a minimum selling price of US$50 per Alcoa share. 12. China Biopharmaceutical (01177.HK): The first patient has been enrolled in the Phase III registration clinical trial of kelfinizumab ("CCR8 monoclonal antibody") as a second-line treatment for gastric cancer. 13. Xinhua Communications Media (00309.HK): Plans to issue 153 million subscription shares to Yu Huilin at a premium of 3.13%. 14. Orient Securities (03958.HK): Plans to acquire 100% equity of Shanghai Securities through the issuance of A-shares and cash payment.